Skip to content
Agentic OS
Menu

Intelligence / Healthtech & medtech market map / Digital health software and connected health technology / Remote monitoring, digital therapeutics and connected-care technology / Pharma and biotech connected clinical-development programs

NicheREVIEWEDResearched 14 Nov 2026 · refreshed weekly

Pharma and biotech connected clinical-development programs

For pharmaceutical and biotechnology companies that need to capture patient-generated data, support protocol execution, monitor safety or adherence, and provide therapy-linked patient support, particularly when decentralized trials, continuous-data requirements, or post-approval evidence needs trigger connected-care procurement. Excludes systems bought directly by providers or payers.

Market size
—
Not sized yet
Growth
—
CAGR
Attractiveness
80 /100
for B2B sellers
Evidence
not sized
1 source · no estimate
Level
Niche
Segmented by
Customer type
Buyers
Pharmaceutical and biotechnology companies
Buying centre
Clinical development, digital health, medical affairs, pharmacovigilance, and health economics and outcomes research define use cases and evidence requirements. Information technology, security, quality, legal, regulatory, procurement, and external-innovation teams evaluate platforms and connected d
Buying triggers
  • Need to recruit or retain patients in clinical trials
  • Protocols requiring continuous data outside research sites
  • Safety, adherence, or real-world evidence requirements
  • Therapy launch or post-approval patient-support programs
Pains
  • Fragmented patient-generated and clinical-trial data
  • High site workload and inconsistent execution across protocols
  • Consent, privacy, validation, and regulatory complexity
  • Slow integration with trial systems and existing clinical workflows
Scores (1–5)
Pain intensity4
Purchasing power5
Reachability3
Growth4

How this was sized

Not sized yet

No cited source quantifies connected-care spending by pharmaceutical and biotechnology buyers or separates clinical-development and post-approval use cases. The connected-health-platform source identifies vendors serving virtual care, device-anchored remote monitoring, analytics, and infrastructure, but provides no buyer-segment allocation [10]. Scores use a 1-5 scale, with 5 highest.

Alongside it in Remote monitoring, digital therapeutics and connected-care technology

// Sell into Pharma and biotech connected clinical-development programs

AOS finds the biggest accounts in this niche with a reason to talk now, maps their buying centre and prepares the outreach for your approval.